OncoMatch/Clinical Trials/NCT06151236
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Is NCT06151236 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination for merkel cell carcinoma.
Treatment: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination — The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage I (≥ 10 MM), IIA, IIB, III (AJCC (8th ed))
Excluded: Stage DISTANT METASTASES
AJCC (8th ed) clinical or pathological stage I (≥ 10 mm), IIA, or IIB or III disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior anti-PD-1, CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease
Cannot have received: chemotherapy
any chemotherapy or experimental local or systemic drug treatment
Lab requirements
Cardiac function
Uncontrolled cardiovascular disease or history of myocarditis; Troponin T (TnT) or I (TnI) >2 × institutional ULN
Uncontrolled cardiovascular disease or history of myocarditis; Troponin T (TnT) or I (TnI) >2 × institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify